Key result
Maternal exposure to medications including lithium and valproic acid is linked to congenital cardiac malformations.
Why the study?
Cardiovascular malformations represent the largest group of congenital anomalies, and several medicinal drugs have been proven to cause them.
Do specific maternal medications increase the risk of cardiovascular malformations in offspring?
Do specific maternal medications increase the risk of cardiovascular malformations in offspring?
Answers are grounded in this paper and cite their sources.
This review highlights the teratogenic risks of specific maternal medications on fetal cardiovascular development and emphasizes the importance of counseling for pregnant women.
Cardiovascular malformations form the largest group of congenital anomalies, typically quoted at 0.8% of all live births.Several medicinal drugs have been proven to cause cardiovascular malformations.We discuss here the risks of the major known medications, including lithium, valproic acid, ondansetron, methylphenidate, topiramate, and the newly recognised dydrogesterone.In contrast, we discuss the controversial and debated effects of selective serotonin reuptake inhibitors (SSR) and selective serotonin norepinephrine reuptake inhibitors (SNRI).Subsequently we describe the principles of counselling pregnant women and those planning pregnancy, who are exposed to these drugs.
No takes yet. Share an insight, caveat, or question.
Gideon Koren (2020) conducted a review in Congenital cardiac malformations. Teratogenic maternal medications (e.g., lithium, valproic acid, ondansetron, dydrogesterone) vs. Unexposed pregnancies was evaluated on Congenital cardiac malformations. Maternal exposure to medications such as lithium, valproic acid, ondansetron, topiramate, methylphenidate, and dydrogesterone during pregnancy is associated with an increased risk of congenital cardiac malformations.
Synapse has enriched 10 related papers. Consider them for comparative context: